Skip to NavigationSkip to content

Novavax and Janssen commit 90 million COVID-19 vaccine doses to UK Government with two new deals

Published on 14/08/20 at 11:49am

The UK Government has signed a new deal with Johnson & Johnson and Novavax to secure 90 million orders of their vaccine candidates to protect against COVID-19 infection.  

One of the announced deals was to reserve 30 million doses of Ad26.COV2.S, the COVID-19 vaccine candidate developed by Janssen, the pharmaceutical subsidiary of J&J, for not-for-profit emergency pandemic use. As part of the deal, the UK Government has the option to purchase a further 22 million doses of the vaccine if required.

The deal with Janssen also includes the UK Government’s commitment to co-funding a global Phase 3 clinical trial of the candidate.

The second, separate deal signed with Novavax earmarked a further 60 million doses of the US biotech’s candidate, and will also help support a Phase 3 study of the drug in partnership with the National Institute for Health Research (NIHR).

These latest two deals bring the UK’s total number of signed agreements concerning the procurement of COVID-19 vaccines to six, meaning they are tied with the US for the greatest number of deals signed by any nation worldwide. In total, the UK has reserved 362 million doses across four different types of therapy candidates. There are around 66 million people living in the UK.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches